188 related articles for article (PubMed ID: 6337292)
21. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
Cheever MA; Greenberg PD; Fefer A
J Natl Cancer Inst; 1981 Jul; 67(1):169-73. PubMed ID: 6942187
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
23. Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity.
Sugahara D; Tsuji-Kawahara S; Miyazawa M
J Virol; 2004 Jun; 78(12):6322-34. PubMed ID: 15163726
[TBL] [Abstract][Full Text] [Related]
24. Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia.
Britt WJ; Chesebro B
J Immunol; 1983 May; 130(5):2363-7. PubMed ID: 6833759
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility and resistance to Moloney murine leukemia virus-induced promonocytic leukemia.
Nazarov V; Hilbert D; Wolff L
Virology; 1994 Dec; 205(2):479-85. PubMed ID: 7975249
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Friend virus leukemia. II. Prevention of friend leukemia by passive administration of immune serum and cells to young mice.
Wahren B
J Natl Cancer Inst; 1968 Oct; 41(4):931-8. PubMed ID: 5693664
[No Abstract] [Full Text] [Related]
27. Effect of non-H-2-linked genes on anti-virus immune responses and long-term survival in mice persistently infected with E-55+ murine leukemia virus.
Avidan N; Tumas-Brundage KM; Sieck TG; Prystowsky MB; Blank KJ
Virology; 1995 Aug; 211(2):507-15. PubMed ID: 7645254
[TBL] [Abstract][Full Text] [Related]
28. Virus and cell requirements for Friend virus granulocytic leukemogenesis in long-term bone marrow cultures of NIH swiss [N:NIH(S)] mice.
Greenberger JS; Newburger PE; Lipton JM; Moloney WC; Sakakeeny MA; Jackson PL
J Natl Cancer Inst; 1980 Apr; 64(4):867-78. PubMed ID: 6928998
[TBL] [Abstract][Full Text] [Related]
29. Treatment of established tumor by adoptive immunotherapy with specifically immune T cells.
Greenberg PD; Cheever MA
Surv Immunol Res; 1985; 4(4):283-96. PubMed ID: 3879738
[No Abstract] [Full Text] [Related]
30. Immunotherapy of murine leukemia VI. Development of immunologic memory in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
Genovesi EV; Livnat D; Collins JJ
Leuk Res; 1982; 6(4):577-93. PubMed ID: 6958931
[TBL] [Abstract][Full Text] [Related]
31. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
32. Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.
Dittmer U; Peterson KE; Messer R; Stromnes IM; Race B; Hasenkrug KJ
J Virol; 2001 Jan; 75(2):654-60. PubMed ID: 11134279
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-induced reversal of immunosuppression by leukemia viruses.
Specter SC; Bendinelli M; Ceglowski WS; Friedman H
Fed Proc; 1978 Jan; 37(1):97-101. PubMed ID: 201505
[TBL] [Abstract][Full Text] [Related]
35. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
[TBL] [Abstract][Full Text] [Related]
36. Effects of tacrolimus on infection of Friend murine leukemia virus to Fv-4 gene heterozygous mice.
Zhang FM; Yang BF; Gu HX; Chen XB; Zhong ZH; Cheng Z
Acta Pharmacol Sin; 2004 Feb; 25(2):208-12. PubMed ID: 14769211
[TBL] [Abstract][Full Text] [Related]
37. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells.
Cheever MA; Greenberg PD; Fefer A
J Immunol; 1978 Dec; 121(6):2220-7. PubMed ID: 152790
[No Abstract] [Full Text] [Related]
38. Immunotherapy of murine leukemia. IX. The requirement for the Fc portion of antibody for successful passive serum therapy of Friend leukemia virus-induced disease.
Collins JJ; Sackie DM; Johnson GR
Virology; 1983 Apr; 126(1):259-66. PubMed ID: 6573816
[TBL] [Abstract][Full Text] [Related]
39. Cellular and serum involvement in protection against Friend leukemia virus.
Schuller GB; Morahan PS
Cancer Res; 1977 Nov; 37(11):4064-9. PubMed ID: 908040
[TBL] [Abstract][Full Text] [Related]
40. In vitro growth inhibition of murine leukemia cells by antibody specific for the major envelope glycoprotein (gp71) of Friend leukemia virus.
Genovesi EV; Collins JJ
J Cell Physiol; 1983 Nov; 117(2):215-29. PubMed ID: 6630299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
